• Conference Proceeding

Quality-Adjusted Survival in Patients with Wild-Type (Wt) Kras Metastatic Colorectal Cancer (Mcrc) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone

Citation

Wang, J., Zhao, Z., Barber, B., Zhang, J., Sherrill, B., Braun, S., ... Douillard, J. (2012). Quality-Adjusted Survival in Patients with Wild-Type (Wt) Kras Metastatic Colorectal Cancer (Mcrc) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone. In [23], pp. 192–193. .

Abstract